A citation-based method for searching scientific literature

Minoli A Perera, Larisa H Cavallari, Nita A Limdi, Eric R Gamazon, Anuar Konkashbaev, Roxana Daneshjou, Anna Pluzhnikov, Dana C Crawford, Jelai Wang, Nianjun Liu, Nicholas Tatonetti, Stephane Bourgeois, Harumi Takahashi, Yukiko Bradford, Benjamin M Burkley, Robert J Desnick, Jonathan L Halperin, Sherief I Khalifa, Taimour Y Langaee, Steven A Lubitz, Edith A Nutescu, Matthew Oetjens, Mohamed H Shahin, Shitalben R Patel, Hersh Sagreiya, Matthew Tector, Karen E Weck, Mark J Rieder, Stuart A Scott, Alan H B Wu, James K Burmester, Mia Wadelius, Panos Deloukas, Michael J Wagner, Taisei Mushiroda, Michiaki Kubo, Dan M Roden, Nancy J Cox, Russ B Altman, Teri E Klein, Yusuke Nakamura, Julie A Johnson. Lancet 2013
Times Cited: 182







List of co-cited articles
852 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A pharmacogenetic versus a clinical algorithm for warfarin dosing.
Stephen E Kimmel, Benjamin French, Scott E Kasner, Julie A Johnson, Jeffrey L Anderson, Brian F Gage, Yves D Rosenberg, Charles S Eby, Rosemary A Madigan, Robert B McBane,[...]. N Engl J Med 2013
526
50

Estimation of the warfarin dose with clinical and pharmacogenetic data.
T E Klein, R B Altman, N Eriksson, B F Gage, S E Kimmel, M-T M Lee, N A Limdi, D Page, D M Roden, M J Wagner,[...]. N Engl J Med 2009
46

A randomized trial of genotype-guided dosing of warfarin.
Munir Pirmohamed, Girvan Burnside, Niclas Eriksson, Andrea L Jorgensen, Cheng Hock Toh, Toby Nicholson, Patrick Kesteven, Christina Christersson, Bengt Wahlström, Christina Stafberg,[...]. N Engl J Med 2013
566
42

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
J A Johnson, K E Caudle, L Gong, M Whirl-Carrillo, C M Stein, S A Scott, M T Lee, B F Gage, S E Kimmel, M A Perera,[...]. Clin Pharmacol Ther 2017
298
41

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.
B F Gage, C Eby, J A Johnson, E Deych, M J Rieder, P M Ridker, P E Milligan, G Grice, P Lenzini, A E Rettie,[...]. Clin Pharmacol Ther 2008
565
32

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.
Fumihiko Takeuchi, Ralph McGinnis, Stephane Bourgeois, Chris Barnes, Niclas Eriksson, Nicole Soranzo, Pamela Whittaker, Venkatesh Ranganath, Vasudev Kumanduri, William McLaren,[...]. PLoS Genet 2009
461
29

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
Mark J Rieder, Alexander P Reiner, Brian F Gage, Deborah A Nickerson, Charles S Eby, Howard L McLeod, David K Blough, Kenneth E Thummel, David L Veenstra, Allan E Rettie. N Engl J Med 2005
28

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups.
Nita A Limdi, Mia Wadelius, Larisa Cavallari, Niclas Eriksson, Dana C Crawford, Ming-Ta M Lee, Chien-Hsiun Chen, Alison Motsinger-Reif, Hersh Sagreiya, Nianjun Liu,[...]. Blood 2010
268
27

Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial.
Brian F Gage, Anne R Bass, Hannah Lin, Scott C Woller, Scott M Stevens, Noor Al-Hammadi, Juan Li, Tomás Rodríguez, J Philip Miller, Gwendolyn A McMillin,[...]. JAMA 2017
144
27

CYP4F2 genetic variant alters required warfarin dose.
Michael D Caldwell, Tarif Awad, Julie A Johnson, Brian F Gage, Mat Falkowski, Paul Gardina, Jason Hubbard, Yaron Turpaz, Taimour Y Langaee, Charles Eby,[...]. Blood 2008
389
26

Race influences warfarin dose changes associated with genetic factors.
Nita A Limdi, Todd M Brown, Qi Yan, Jonathan L Thigpen, Aditi Shendre, Nianjun Liu, Charles E Hill, Donna K Arnett, T Mark Beasley. Blood 2015
66
31

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.
Gregory M Cooper, Julie A Johnson, Taimour Y Langaee, Hua Feng, Ian B Stanaway, Ute I Schwarz, Marylyn D Ritchie, C Michael Stein, Dan M Roden, Joshua D Smith,[...]. Blood 2008
319
21

Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese.
Pei-Chieng Cha, Taisei Mushiroda, Atsushi Takahashi, Michiaki Kubo, Shiro Minami, Naoyuki Kamatani, Yusuke Nakamura. Hum Mol Genet 2010
104
21

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.
Simone Rost, Andreas Fregin, Vytautas Ivaskevicius, Ernst Conzelmann, Konstanze Hörtnagel, Hans-Joachim Pelz, Knut Lappegard, Erhard Seifried, Inge Scharrer, Edward G D Tuddenham,[...]. Nature 2004
807
20

The largest prospective warfarin-treated cohort supports genetic forecasting.
Mia Wadelius, Leslie Y Chen, Jonatan D Lindh, Niclas Eriksson, Mohammed J R Ghori, Suzannah Bumpstead, Lennart Holm, Ralph McGinnis, Anders Rane, Panos Deloukas. Blood 2009
409
18

Genetic and clinical predictors of warfarin dose requirements in African Americans.
L H Cavallari, T Y Langaee, K M Momary, N L Shapiro, E A Nutescu, W A Coty, M A G Viana, S R Patel, J A Johnson. Clin Pharmacol Ther 2010
148
18

Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Jessica L Mega, Joseph R Walker, Christian T Ruff, Alexander G Vandell, Francesco Nordio, Naveen Deenadayalu, Sabina A Murphy, James Lee, Michele F Mercuri, Robert P Giugliano,[...]. Lancet 2015
123
17

Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans.
Katarzyna Drozda, Shan Wong, Shitalben R Patel, Adam P Bress, Edith A Nutescu, Rick A Kittles, Larisa H Cavallari. Pharmacogenet Genomics 2015
54
29

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.
J A Johnson, L Gong, M Whirl-Carrillo, B F Gage, S A Scott, C M Stein, J L Anderson, S E Kimmel, M T M Lee, M Pirmohamed,[...]. Clin Pharmacol Ther 2011
437
16

The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.
M A Perera, E Gamazon, L H Cavallari, S R Patel, S Poindexter, R A Kittles, D Nicolae, N J Cox. Clin Pharmacol Ther 2011
85
18

SLCO1B1 variants and statin-induced myopathy--a genomewide study.
E Link, S Parish, J Armitage, L Bowman, S Heath, F Matsuda, I Gut, M Lathrop, R Collins. N Engl J Med 2008
13



Association of warfarin dose with genes involved in its action and metabolism.
Mia Wadelius, Leslie Y Chen, Niclas Eriksson, Suzannah Bumpstead, Jilur Ghori, Claes Wadelius, David Bentley, Ralph McGinnis, Panos Deloukas. Hum Genet 2007
288
12

Genetic variant in folate homeostasis is associated with lower warfarin dose in African Americans.
Roxana Daneshjou, Eric R Gamazon, Ben Burkley, Larisa H Cavallari, Julie A Johnson, Teri E Klein, Nita Limdi, Sara Hillenmeyer, Bethany Percha, Konrad J Karczewski,[...]. Blood 2014
43
27

CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant.
Matthew G McDonald, Mark J Rieder, Mariko Nakano, Clara K Hsia, Allan E Rettie. Mol Pharmacol 2009
219
12

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.
S A Scott, K Sangkuhl, C M Stein, J-S Hulot, J L Mega, D M Roden, T E Klein, M S Sabatine, J A Johnson, A R Shuldiner. Clin Pharmacol Ther 2013
613
12

Warfarin pharmacogenetics.
Julie A Johnson, Larisa H Cavallari. Trends Cardiovasc Med 2015
89
13

VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.
Nita A Limdi, T Mark Beasley, Michael R Crowley, Joyce A Goldstein, Mark J Rieder, David A Flockhart, Donna K Arnett, Ronald T Acton, Nianjun Liu. Pharmacogenomics 2008
90
13

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
Alan R Shuldiner, Jeffrey R O'Connell, Kevin P Bliden, Amish Gandhi, Kathleen Ryan, Richard B Horenstein, Coleen M Damcott, Ruth Pakyz, Udaya S Tantry, Quince Gibson,[...]. JAMA 2009
12

Pharmacogenetics of warfarin: current status and future challenges.
M Wadelius, M Pirmohamed. Pharmacogenomics J 2007
226
11

Genetic determinants of response to clopidogrel and cardiovascular events.
Tabassome Simon, Céline Verstuyft, Murielle Mary-Krause, Lina Quteineh, Elodie Drouet, Nicolas Méneveau, P Gabriel Steg, Jean Ferrières, Nicolas Danchin, Laurent Becquemont. N Engl J Med 2009
11

A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.
D Voora, D C Koboldt, C R King, P A Lenzini, C S Eby, R Porche-Sorbet, E Deych, M Crankshaw, P E Milligan, H L McLeod,[...]. Clin Pharmacol Ther 2010
73
15

The future of warfarin pharmacogenetics in under-represented minority groups.
Larisa H Cavallari, Minoli A Perera. Future Cardiol 2012
52
21

Genome-wide association study of warfarin maintenance dose in a Brazilian sample.
Esteban J Parra, Mariana R Botton, Jamila A Perini, S Krithika, Stephane Bourgeois, Todd A Johnson, Tatsuhiko Tsunoda, Munir Pirmohamed, Mia Wadelius, Nita A Limdi,[...]. Pharmacogenomics 2015
22
50

Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans.
W Hernandez, E R Gamazon, K Aquino-Michaels, S Patel, T J O'Brien, A F Harralson, R A Kittles, A Barbour, M Tuck, S D McIntosh,[...]. Pharmacogenomics J 2014
52
21

Association of Genetic Variants With Warfarin-Associated Bleeding Among Patients of African Descent.
Tanima De, Cristina Alarcon, Wenndy Hernandez, Ina Liko, Larisa H Cavallari, Julio D Duarte, Minoli A Perera. JAMA 2018
21
52

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
Mitchell K Higashi, David L Veenstra, L Midori Kondo, Ann K Wittkowsky, Sengkeo L Srinouanprachanh, Fred M Farin, Allan E Rettie. JAMA 2002
791
10

The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.
L B Ramsey, S G Johnson, K E Caudle, C E Haidar, D Voora, R A Wilke, W D Maxwell, H L McLeod, R M Krauss, D M Roden,[...]. Clin Pharmacol Ther 2014
257
10

Cytochrome p-450 polymorphisms and response to clopidogrel.
Jessica L Mega, Sandra L Close, Stephen D Wiviott, Lei Shen, Richard D Hockett, John T Brandt, Joseph R Walker, Elliott M Antman, William Macias, Eugene Braunwald,[...]. N Engl J Med 2009
10

Pharmacogenomics knowledge for personalized medicine.
M Whirl-Carrillo, E M McDonagh, J M Hebert, L Gong, K Sangkuhl, C F Thorn, R B Altman, T E Klein. Clin Pharmacol Ther 2012
10

A genome-wide association study of acenocoumarol maintenance dosage.
Martina Teichert, Mark Eijgelsheim, Fernando Rivadeneira, Andre G Uitterlinden, Ron H N van Schaik, Albert Hofman, Peter A G M De Smet, Teun van Gelder, Loes E Visser, Bruno H Ch Stricker. Hum Mol Genet 2009
124
10

Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.
Nita A Limdi, Donna K Arnett, Joyce A Goldstein, T Mark Beasley, Gerald McGwin, Brian K Adler, Ronald T Acton. Pharmacogenomics 2008
118
10

A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon.
Talitha I Verhoef, Georgia Ragia, Anthonius de Boer, Rita Barallon, Genovefa Kolovou, Vana Kolovou, Stavros Konstantinides, Saskia Le Cessie, Efstratios Maltezos, Felix J M van der Meer,[...]. N Engl J Med 2013
170
10

Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans.
Adam Bress, Shitalben R Patel, Minoli A Perera, Richard T Campbell, Rick A Kittles, Larisa H Cavallari. Pharmacogenomics 2012
47
21

Genomics is failing on diversity.
Alice B Popejoy, Stephanie M Fullerton. Nature 2016
723
10

Genetic determinants of response to warfarin during initial anticoagulation.
Ute I Schwarz, Marylyn D Ritchie, Yuki Bradford, Chun Li, Scott M Dudek, Amy Frye-Anderson, Richard B Kim, Dan M Roden, C Michael Stein. N Engl J Med 2008
425
9

Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients.
Mohamed Hossam A Shahin, Sherief I Khalifa, Yan Gong, Lamiaa N Hammad, Mohamed T H Sallam, Mostafa El Shafey, Shawky S Ali, Mohamed-Eslam F Mohamed, Taimour Langaee, Julie A Johnson. Pharmacogenet Genomics 2011
74
12

Oral anticoagulation: a critique of recent advances and controversies.
Munir Pirmohamed, Farhad Kamali, Ann K Daly, Mia Wadelius. Trends Pharmacol Sci 2015
54
16

Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism.
Y Liu, H Jeong, H Takahashi, K Drozda, S R Patel, N L Shapiro, E A Nutescu, L H Cavallari. Clin Pharmacol Ther 2012
67
13


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.